Overview

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Collaborator:

Celgene

Treatments:

Luspatercept